Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy

被引：26
作者：
Awasthi, Rakesh [1 ,5 ]
Maier, Harald J. [2 ]
Zhang, Jie [3 ]
Lim, Stephen [4 ]
机构：
[1] Novartis Inst Biomed Res, E Hanover, NJ USA
[2] Novartis Pharm AG, Oncol & Hematol, Global Drug Dev, Basel, Switzerland
[3] Novartis Serv Inc, Cell & Gene Unit, E Hanover, NJ USA
[4] Novartis Pharmaceut, US Med Affairs, Oncol, E Hanover, NJ USA
[5] Novartis Inst Biomed Res, Oncol & Hematol, One Hlth Plaza, E Hanover, NJ 07936 USA
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 01期
关键词：
Cell and gene therapy; CAR-T therapy; clinical development; immunotherapy; leukemia; lymphoma; B-CELL LYMPHOMA; UNITED-STATES; OUTCOMES; JULIET; MANAGEMENT; 2ND-LINE;
D O I：
10.1080/21645515.2023.2210046
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah (R) (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.
引用
收藏
页数：8
相关论文
共 47 条
  • [1] [Anonymous], 2018, CHIM ANT REC T CELL
  • [2] Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL
    Awasthi, Rakesh
    Pacaud, Lida
    Waldron, Edward
    Tam, Constantine S.
    Jager, Ulrich
    Borchmann, Peter
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Marie Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    del Corral, Christopher
    Chu, Jufen
    Gershgorin, Irina
    Pruteanu-Malinici, Iulian
    Chakraborty, Abhijit
    Mueller, Karen Thudium
    Waller, Edmund K.
    [J]. BLOOD ADVANCES, 2020, 4 (03) : 560 - 572
  • [3] Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients
    Awasthi, Rakesh
    Mueller, Karen Thudium
    Yanik, Gregory A.
    Tam, Constantine S.
    Rives, Susana
    McGuirk, Joseph P.
    Pulsipher, Michael A.
    Boyer, Michael W.
    Jaeger, Ulrich
    Baruchel, Andre
    Myers, Gary Douglas
    Balke-Want, Hyatt
    Schuster, Stephen J.
    Stefanski, Heather
    Bishop, Michael R.
    Waldron, Edward R.
    Anak, Ozlem
    Chakraborty, Abhijit
    Bleickardt, Eric
    Wong, Stephane
    Pacaud, Lida Bubuteishvili
    Waller, Edmund K.
    Maude, Shannon L.
    [J]. BLOOD, 2018, 132
  • [4] CAR-T Therapy Displays Favorable Gains in Health Outcomes and Competitive Cost-Effectiveness When Compared with Past Innovative Cancer Treatments
    Baumgardner, James
    Everson, Katie
    Brauer, Michelle
    Zhang, Jie
    Hao, Yanni
    Liu, Jamae
    Lakdawalla, Darius N.
    [J]. BLOOD, 2018, 132
  • [5] Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?
    Bear, Adham S.
    Morgan, Richard A.
    Cornetta, Kenneth
    June, Carl H.
    Binder-Scholl, Gwendolyn
    Dudley, Mark E.
    Feldman, Steven A.
    Rosenberg, Steven A.
    Shurtleff, Sheila A.
    Rooney, Cliona M.
    Heslop, Helen E.
    Dotti, Gianpietro
    [J]. MOLECULAR THERAPY, 2012, 20 (02) : 246 - 249
  • [6] Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
    Bishop, M. R.
    Dickinson, M.
    Purtill, D.
    Barba, P.
    Santoro, A.
    Hamad, N.
    Kato, K.
    Sureda, A.
    Greil, R.
    Thieblemont, C.
    Morschhauser, F.
    Janz, M.
    Flinn, I
    Rabitsch, W.
    Kwong, Y-L
    Kersten, M. J.
    Minnema, M. C.
    Holte, H.
    Chan, E. H. L.
    Martinez-Lopez, J.
    Mueller, A. M. S.
    Maziarz, R. T.
    McGuirk, J. P.
    Bachy, E.
    Le Gouill, S.
    Dreyling, M.
    Harigae, H.
    Bond, D.
    Andreadis, C.
    McSweeney, P.
    Kharfan-Dabaja, M.
    Newsome, S.
    Degtyarev, E.
    Awasthi, R.
    del Corral, C.
    Andreola, G.
    Masood, A.
    Schuster, S. J.
    Jaeger, U.
    Borchmann, P.
    Westin, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) : 629 - 639
  • [7] Toxicities of chimeric antigen receptor T cells: recognition and management
    Brudno, Jennifer N.
    Kochenderfer, James N.
    [J]. BLOOD, 2016, 127 (26) : 3321 - 3330
  • [8] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
    Crump, Michael
    Neelapu, Sattva S.
    Farooq, Umar
    Van den Neste, Eric
    Kuruvilla, John
    Westin, Jason
    Link, Brian K.
    Hay, Annette
    Cerhan, James R.
    Zhu, Liting
    Boussetta, Sami
    Feng, Lei
    Maurer, Matthew J.
    Navale, Lynn
    Wiezorek, Jeff
    Go, William Y.
    Gisselbrecht, Christian
    [J]. BLOOD, 2017, 130 (16) : 1800 - 1808
  • [9] Dreyling M., 2022, AM SOC HEM ASH ANN M
  • [10] Flinn IW, 2021, Blood, V138, P1, DOI [10.1182/blood-2021- 146268, DOI 10.1182/BLOOD-2021-146268]
12345